The Danish laboratory Novo Nordisk has just announced the transfer to Chartres (Eure-et-Loir) of a production line for anti-diabetics manufactured until now in Kalundborg (Denmark). “We export this drug all over the world, except the United States where the group already has a factory,” says Lone Charlotte Larsen, director of the plant in Chartres.
This transfer, which will be completed in July 2022, will not directly create new jobs. On the one hand, the line is highly automated, and the site’s workforce, which is 1,200 employees, excluding temporary workers, does not require job creation, indicates management. But “Novo Nordisk still needs qualified personnel to replace departures and retirements. On average, we are on a wheel of 30 to 50 recruitments per year ”, explains Lone Charlotte Larsen.